Simplex Trading
GLUE icon

Simplex Trading’s Monte Rosa Therapeutics GLUE Stock Holding History

Simplex Trading’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$400K Buy
24,300
+23,000
+1,769% +$440K ﹤0.01% 3534
2025
Q4 		$20.4K Sell
1,300
-38,000
-97% -$512K ﹤0.01% 6461
2025
Q3 		$291K Buy
39,300
+6,300
+19% +$33.4K ﹤0.01% 4499
2025
Q2 		$148K Buy
33,000
+23,100
+233% +$103K ﹤0.01% 4815
2025
Q1 		$45K Sell
9,900
-22,900
-70% -$140K ﹤0.01% 5874
2024
Q4 		$227K Buy
32,800
+4,600
+16% +$34.5K ﹤0.01% 4389
2024
Q3 		$149K Buy
28,200
+12,200
+76% +$61.6K ﹤0.01% 4824
2024
Q2 		$59K Sell
16,000
-900
-5% -$4.59K ﹤0.01% 5907
2024
Q1 		$119K Buy
16,900
+7,300
+76% +$43.3K ﹤0.01% 5412
2023
Q4 		$54K Buy
9,600
+4,600
+92% +$18K ﹤0.01% 6010
2023
Q3 		$23K Sell
5,000
-6,000
-55% -$38.6K ﹤0.01% 6499
2023
Q2 		$75K Buy
11,000
+400
+4% +$2.59K ﹤0.01% 5409
2023
Q1 		$82K Hold
10,600
– – ﹤0.01% 5382
2022
Q4 		$80K Buy
+10,600
New +$88.3K ﹤0.01% 5336

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Simplex Trading's GLUE Position: Q1 2026 in Review

Simplex Trading reduced its Monte Rosa Therapeutics (GLUE) stake by 58% in Q1 2026, selling an estimated $390K and leaving 14,710 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #4068.

Simplex Trading first reported a position in GLUE in Q3 2023 and has held it in 6 quarters since. The position peaked at $551K in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Simplex Trading held 14,710 shares of Monte Rosa Therapeutics worth $242K as of Q1 2026.
  • Simplex Trading sold 20,414 Monte Rosa Therapeutics shares in Q1 2026, an estimated $390K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #4068 holding.
  • Simplex Trading first reported a position in Monte Rosa Therapeutics in Q3 2023 and has held it in 6 quarters since.
  • Simplex Trading's Monte Rosa Therapeutics position peaked at $551K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.